Capricor Therapeutics (NASDAQ:CAPR) Trading 6.2% Higher – Should You Buy?

by · The Markets Daily

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) were up 6.2% on Friday . The company traded as high as $27.41 and last traded at $27.41. Approximately 1,121,213 shares changed hands during trading, a decline of 5% from the average daily volume of 1,184,921 shares. The stock had previously closed at $25.82.

Wall Street Analyst Weigh In

Several research analysts have commented on CAPR shares. Roth Mkm boosted their price target on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. UBS Group set a $50.00 target price on Capricor Therapeutics in a report on Monday, December 15th. B. Riley Financial restated a “buy” rating and issued a $50.00 price target (up from $21.00) on shares of Capricor Therapeutics in a research note on Monday, December 15th. Finally, Maxim Group upped their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Check Out Our Latest Analysis on CAPR

Capricor Therapeutics Trading Up 6.4%

The business has a 50 day moving average price of $25.41 and a 200-day moving average price of $15.51. The firm has a market capitalization of $1.26 billion, a PE ratio of -15.27 and a beta of 0.37.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares during the last quarter. Suvretta Capital Management LLC acquired a new stake in Capricor Therapeutics during the 4th quarter valued at $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics during the fourth quarter worth $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics in the fourth quarter worth $43,516,000. Finally, Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after acquiring an additional 55,766 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

Featured Articles